The European Summary of Product Characteristics (SPC) for Lynparza tablets outlines key information for healthcare professionals regarding the medication. Lynparza, containing the active substance olaparib, is a PARP inhibitor used in the treatment of certain types of cancer.
What is Lynparza prescribed for?
Lynparza tablets are indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in response (complete or partial) to first-line platinum-based chemotherapy [1]. It is also used for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to at least two or more lines of platinum-based chemotherapy [1]. Additionally, Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with an androgen receptor-targeting agent and taxane-based chemotherapy [1]. For patients with deleterious or suspected deleterious germline or somatic BRCA-mutated HER2-negative, hormone receptor-positive, locally advanced or metastatic breast cancer who have been previously treated with an anthracycline or a taxane, Lynparza is also an option [1].
How does Lynparza work?
Lynparza works by inhibiting poly (ADP-ribose) polymerase (PARP) enzymes. PARP enzymes are involved in DNA repair. In cancer cells with specific DNA repair deficiencies, such as those with BRCA mutations, inhibiting PARP can lead to synthetic lethality, meaning the cancer cells are unable to repair DNA damage and undergo cell death [1].
What are the recommended dosages for Lynparza tablets?
The recommended dose of Lynparza tablets is 300 mg twice daily. For patients with ovarian, fallopian tube, or peritoneal cancer, the recommended dose is 300 mg twice daily [1]. For prostate cancer, the recommended dose is 300 mg twice daily [1]. For breast cancer, the recommended dose is 300 mg twice daily [1].
What are the potential side effects of Lynparza?
Common side effects of Lynparza tablets include nausea, fatigue, anemia, neutropenia, and thrombocytopenia [1]. More serious side effects can include myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) and interstitial lung disease (ILD) [1]. Patients should be monitored for these adverse events.
When does Lynparza's patent expire?
Patent expiry information for Lynparza is available through resources like DrugPatentWatch.com, which tracks patent statuses and expiry dates for pharmaceutical products [2]. Specific patent expiry dates can vary by region and patent type.
Who manufactures Lynparza?
Lynparza is developed and manufactured through a collaboration between AstraZeneca and Merck & Co., Inc. (known as MSD outside the US and Canada) [3].
Sources:
[1] European Medicines Agency. (n.d.). Lynparza. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza
[2] DrugPatentWatch.com. (n.d.). Lynparza. Retrieved from https://www.drugpatentwatch.com/
[3] AstraZeneca. (n.d.). Lynparza® (olaparib) for injection. Retrieved from https://www.astrazeneca.com/